Spark Therapeutics Enters Into Definitive Merger Agreement With Roche

PandaTip: “Reflection” is an essential part of any contract. This is the value that both parties promise; Exchange of value that encourages both parties to enter into the contract. In the case of this contract for the sale of intellectual property, the “reflection” was written by the assignee as a sale of intellectual property in exchange for the obligation for the agent to use the intellectual property for commercial purposes and to return the proceeds of that “exploitation” to the transfer of the intellectual property. EX-99.1 Exhibit 99.1 Spark Therapeutics Announces $350.0 Million Public Offering PHILADELPHIA, August 3, 2017? Spark Therapeutics, Inc. Spark?) (NASDAQ: ONCE) today announced the pricing of a subscribed public offering of 4,605,264 common shares, pursuant to an automatic and effective registration statement previously filed with Den Securities and Exchan Tenant: Spark Therapeutics, Inc. Premises: 3025 Market St., Suites 016, 026, 200, 300 & 400 FIRST LEASE AMENDMENT This first lease amendment (“Amendment”) will be made and entered into effective October 1, 2018 by and between BRANDYWINE 3025 MARKET, LP, a Pennsylvania Limited Partnership (“Lessors”), and SPARK THERAPEUTICS, INC., a Delaware company (“Tenant”). A.Owners and tenants are parties The Roche Group, headquartered in Basel, Switzerland, is active in more than 100 countries and employed approximately 94,000 people worldwide in 2018. In 2018, Roche invested CHF 11 billion in research and development and generated sales of CHF 56.8 billion. Genentech in the United States is a 100% member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical in Japan. For more information, see www.roche.com. Roche is the world`s largest biotechnology company with differentiated medicines in the fields of oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro and tissue diagnostics of cancer and is at the forefront of diabetes management.

Spark Therapeutics will continue to operate in Philadelphia as an independent company within the Roche Group. Appendix 10.1 CONSULTATION AGREEMENT This advisory agreement (the “Agreement”), which was adopted by 12 Spark Therapeutics, Inc., a Delaware corporation with address at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (the “Company”), and John P. Furey, an individual residing at 446 Boxwood Road, Bryn Mawr, PA 19010 (the “Consultant”), is entered into. INTRODUCTION Appendix 10.37 Confidential documents omitted and submitted separately to the Securities and Exchange Commission. Double asterisks mark omissions. LICENSING AND COMMERCIALIZATION AGREEMENT FOR AND BETWEEN SPARK THERAPEUTICS, INC. AND NOVARTIS PHARMA AG January 24, 2018 ActiveUS 166647742v.1 TABLE OF CONTENTS DEFINITIONS; INTERPRETATION 1 1.1Definitions 1 1.2 Other definitions 11 1.3Interpretatio EX-3.2 Annex 3.2 AMENDED AND ADAPTED STATUTES OF SPARK THERAPEUTICS, INC. * * * * * ARTICLE 1 BUREAUX Section 1.01. . . .